Targeting the NMDA Glutamate Receptor as a Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression

ID Number 13-0389

Principal Investigator(s)
James Murrough

Department(s) or Division(s)


The purpose of the current study is to investigate the safety, tolerability, and efficacy of Nuedexta as a novel antidepressant treatment for individuals suffering from Treatment Resistant Major Depressive Disorder and who have inadequately responded to antidepressant therapy in the past. Like Ketamine, which has been shown to improve mood in depressed patients, Nuedexta targets the same NMDA glutamate receptors in the brain and is believed to have similar positive effects on mood as Ketamine. Nuedexta is a take-home medication currently approved by the Food and Drug Administration (FDA), but is still considered experimental for depression. 

One may qualify to take part in this research study if s/he has been diagnosed with major depressive disorder (MDD) and has not responded to past treatments. Participation in this study is expected to last about 8 weeks. Eligible participants will receive treatment at no cost and compensation for their time.

Contact Information
Betsy Wade
(212) 241-6349

Recruiting Patients: Yes